Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have showed how, in KRAS-mutant CRC, PI3K activation is mediated by RTK signaling, despite KRAS being capable of cross-activating PI3K [20, 28, 29]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“However, therapeutic efficacies are low in most cancers with KRAS or BRAF mutations [13, 14].”
BackgroundAKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · cited 1×
“We next analyzed the phosphorylation of upstream RTKs in order to understand the mechanisms of the reactivation of AKT and ERK after the AKTi and/or MEKi treatments by using the phospho-RTK arrays [4, 5, 29].”
MethodA combinatorial strategy for treating KRAS-mutant lung cancer
Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403
Duncia, J. V., Santella, J. B., Higley, C. A., Pitts, W. J., Wityak, J., Frietze, W. E., Rankin, F. W., Sun, J.-H., Earl, R. A., Tabaka, A. C., et al. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00522-8 · Cited by 401 · cited 4×
“Lapatinib, OSI-906, jnj38877605, MK2206, and U0126 were purchased from Selleck Chemicals.”
MethodInfluentialYang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216 · cited 1×
“However, many cancers, such as colorectal cancers, contain KRAS/BRAF mutant genes and are resistant to MEKi, BRAFi, or RTKis treatments [24, 40, 41].”
BackgroundEbi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
Research works printed but not linked: 33
- Schlessinger, 2010, Cell signaling by receptor tyrosine kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011 · DOI · Paper page
- Rebai, 2011, Receptor tyrosine kinases: from biology to pathology, J Recept Signal Transduct Res, 31, 387, 10.3109/10799893.2011.625425 · DOI
- Morrison, 2012, Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy, Genes Dev, 26, 641, 10.1101/gad.186965.112 · DOI · Paper page
- Kholodenko, 2013, Complexity of receptor tyrosine kinase signal processing, Cold Spring Harb Perspect Biol, 5, a009043, 10.1101/cshperspect.a009043 · DOI
- Lane, 2005, ERBB receptors and cancer: the complexity of targeted inhibitors, Nat Rev Cancer, 5, 341, 10.1038/nrc1609 · DOI · Paper page
- Clark, 2000, The importance of being K-Ras, Cell Signal, 12, 425, 10.1016/S0898-6568(00)00084-X · DOI
- Sawyers, 2002, The phosphatidylinositol 3-Kinase AKT pathway in human cancer, Nat Rev Cancer, 2, 489, 10.1038/nrc839 · DOI · Paper page
- Mozzillo, 2012, The role of BRAF V600 mutation in melanoma, J Transl Med, 10, 85, 10.1186/1479-5876-10-85 · DOI · Paper page
- Clausen, 2015, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol Sci, 36, 422, 10.1016/j.tips.2015.04.005 · DOI · Paper page
- Geng, 2014, Molecularly targeted cancer therapy: some lessons from the past decade, Trends Pharmacol Sci, 35, 41, 10.1016/j.tips.2013.11.004 · DOI · Paper page
- Hojjat-Farsangi, 2014, Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies, Int J Mol Sci, 15, 13768, 10.3390/ijms150813768 · DOI · Paper page
- Hardingham, 2014, KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model, Gastrointest Cancer Res, 7, 23
- Carvajal, 2016, Treatment of Uveal Melanoma, Cancer Treat Res, 167, 281, 10.1007/978-3-319-22539-5_12 · doi:10.1007/978-3-319-22539-5_12
- Settleman, 2008, Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma, Cancer Res, 68, 4853, 10.1158/0008-5472.CAN-07-6787 · DOI · Paper page
- Lukacs, 2014, Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors, Cancer Cell, 25, 697, 10.1016/j.ccr.2014.03.011 · DOI · Paper page
- Weber, 2016, Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas, Oncotarget, 7, 2734, 10.18632/oncotarget.6548 · DOI
- Fakih, 2015, Metastatic colorectal cancer: current state and future directions, J Clin Oncol, 33, 1809, 10.1200/JCO.2014.59.7633 · DOI · Paper page
- Jemal, 2016, Global Cancer Incidence and Mortality Rates and Trends—An Update, Cancer Epidemiol Biomarkers Prev, 25, 16, 10.1158/1055-9965.EPI-15-0578 · DOI · Paper page
- Bray, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 · DOI · Paper page
- Schilsky, 2016, Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015, J Clin Oncol, 34, 179, 10.1200/JCO.2015.63.9674 · DOI · Paper page
- De, 2015, COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Res, 43, D805, 10.1093/nar/gku1075 · DOI · Paper page
- Yan, 2009, Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor, Cancer Research, 69, DDT01
- Gilmer, 2001, The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo, Mol Cancer Ther, 1, 85
- Ji, 2009, Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor, Future Med Chem, 1, 1153, 10.4155/fmc.09.89 · DOI · Paper page
- Comoglio, 2011, Ron kinase transphosphorylation sustains MET oncogene addiction, Cancer Res, 71, 1945, 10.1158/0008-5472.CAN-10-2100 · DOI
- Bardelli, 2014, RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells, Cell Rep, 8, 1475, 10.1016/j.celrep.2014.07.033 · DOI · Paper page
- Yamakawa, 2002, The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells, Clin Cancer Res, 8, 1957
- Alessi, 2011, Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1, Biochem J, 433, 357, 10.1042/bj20101732 · DOI
- Tavare, 2011, Akt signalling in health and disease, Cell Signal, 23, 1515, 10.1016/j.cellsig.2011.05.004 · DOI · Paper page
- Quon, 2001, Tyr(612) and Tyr(632) in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells, Endocrinology, 142, 2833, 10.1210/endo.142.7.8283 · doi:10.1210/endo.142.7.8283 · Paper page
- Rosen, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res, 66, 1500, 10.1158/0008-5472.CAN-05-2925 · DOI · Paper page
- Tsatsakis, 2015, Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review), International Journal of Oncology, 10.3892/ijo.2015.3306 · DOI · Paper page
- Lupinacci, 2014, Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers, Clin Cancer Res, 20, 5672, 10.1158/1078-0432.CCR-14-0868 · DOI · Paper page
Cited by
Vitiello, P. P., Cardone, C., Martini, G., Ciardiello, D., Belli, V., Matrone, N., Barra, G., Napolitano, S., Della Corte, C., Turano, M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1035-0 · Cited by 96
Metadata
- Authors
- Song, Q., Sun, X., Guo, H., & Yu, Q.
- Affiliations
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-12-17
- Volume
- 8
- Issue
- 3
- Pages
- 5003-5015
- ISSN
- 1949-2553
- Cited by
- 18
- References
- 9
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. https://app.cochat.ai/papers/10.18632/oncotarget.14009
- The paper
- Song, Q., Sun, X., Guo, H., & Yu, Q. (2017). Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. Oncotarget. https://doi.org/10.18632/oncotarget.14009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.